Navigation Links
Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
Date:3/6/2009

NEW YORK, March 6 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. today announced after consultation with the U.S. Food and Drug Administration (FDA), that additional clinical studies of aclidinium bromide for the treatment of chronic obstructive pulmonary disease (COPD) will be conducted to provide further support for the selected regimens, including higher and/or more frequent doses. This decision follows a meeting with the FDA to review the previously reported ACCLAIM/COPD I and II studies. The Companies originally anticipated filing a New Drug Application (NDA) in the fourth quarter of 2009 or the first quarter of 2010, pending FDA feedback. Timelines for the development of the additional clinical studies and the future filing date of an NDA, including the ACCLAIM studies, are being determined.

(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )

About COPD

The World Health Organization (WHO) has described COPD as a global epidemic; an estimated 210 million people have COPD worldwide and more than 3 million people died of the condition in 2005, which is equal to 5% of all deaths globally that year. Total deaths from COPD are projected to increase by more than 30% in the next 10 years without interventions to cut risks, particularly exposure to tobacco smoke.

The most common symptoms of COPD are breathlessness (or a "need for air"), abnormal sputum (a mix of saliva and mucus in the airway), and a chronic cough. Daily activities, such as walking up a short flight of stairs or carrying a suitcase, can become very difficult as the condition gradually worsens(1). There are significant unmet needs in the treatment of COPD including limited therapeutic
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
2. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
3. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
4. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)...  Celsion Corporation (NASDAQ: CLSN ) ... conference call to discuss year-end 2014 financial results ... for ThermoDox®, its proprietary heat-activated liposomal encapsulation of ... and TheraSilence™, in immunotherapy and RNA delivery at ... To participate in the call, interested parties may ...
(Date:3/5/2015)... , March 5, 2015 LUNGevity Foundation, ... Food and Drug Administration,s (FDA) approval of Bristol ... and other immunotherapy treatments add another critical new ... the power of a patient,s own immune system ... been approved specifically for patients with squamous cell ...
(Date:3/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/4q7gwz/india_pharma ) has ... 2015: Accelerating growth to the next level - Moving ... their offering. Domestic sales improved in ... by the market,s reaction to the new drug pricing ... be healthy, as the momentum continues and improving economic ...
Breaking Medicine Technology:Celsion Corporation to Hold Year-End 2014 Financial Results Conference Call on Thursday, March 12, 2015 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 2LUNGevity Foundation Applauds FDA Approval of Immunotherapy Drug Opdivo 3India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3
(Date:3/5/2015)... As a result of the American ... Clearstream, LLC ’s products, services and company philosophies, ... products—led by their mPulse Hand Sanitizer—fits the core ... The AAPA—which represents a profession comprising than 100,000 ... specialties in the U.S.—advocates and educates on behalf ...
(Date:3/5/2015)... California (PRWEB) March 05, 2015 ... last week released a special issue ... the field of PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders ... Syndromes), an autoimmune reaction triggered by infections such ... which result in inflammation of the child's brain. ...
(Date:3/5/2015)... March 05, 2015 Wimbledon Health ... provides vascular, echocardiogram and NCV testing, announced ... the Chief Medical Officer. Dr. Artel will be responsible ... of the WimbledonMED program and the continued growth and ... about working with Wimbledon Health Partners as a consulting ...
(Date:3/5/2015)... March 5, 2015 – As National Patient Safety Awareness ... children’s hospitals around the country are affirming the critical ... safe as possible for their children. , A national ... Safety (SPS) and the Children’s Hospital Association—are collaborating to ... the hospital with their child. , “SPS is ...
(Date:3/5/2015)... The MTC 5-day Fundamental Implantology Course has ... a variety of dental disciplines, to offer implant placement ... the onset we wanted this course to be a ... the excellence of the lecturers and the sheer energy ... than satisfied our aims." , Unlike large-scale training ...
Breaking Medicine News(10 mins):Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 2Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 3Health News:Children’s Hospitals Offer Safety Tips for Patient Families During National Patient Safety Awareness Week 4Health News:MIS Global Training Center (MTC) Launches its Fundamental Implantology Course for Doctors - with a Difference 2
... Creates ... ... (Vocus) April 14, 2010 -- PMSI , one of the nation’s largest providers ... the nation’s leader in pain medication monitoring solutions, today announced a strategic partnership to ...
... in Alaska have discovered that lingering oil from the 1989 ... more than 20 years after the disaster. The research, published ... reveal long-term exposure to oil in harlequin ducks and demonstrates ... than years. The Exxon Valdez tanker ran aground on ...
... ... by HealthGrades, April 8, at the 2010 DTC National Conference. , ... Florham Park, N.J. (PRWEB) April 14, ... company for direct-to-consumer (DTC) marketing, today announced the winners of the 10th annual ...
... therapy, study found , WEDNESDAY, April 14 (HealthDay News) ... for developing blood clots, especially if they,re undergoing hormone ... it is important to consider thromboembolic [blood-clotting] side effects ... require endocrine treatment," said Mieke van Hemelrijck, lead author ...
... ... , ... 14, 2010 -- Tahitian Noni International (TNI) announced that just one month after ... have increased dramatically. Sales in North America have skyrocketed, and double digit growth was common ...
... ... Living Green and “Tip of the Day” at www.greenearthcleaning.com , featuring 365 easy ways ... ... environmentally friendly dry cleaning, GreenEarth Cleaning, LLC announced today the launch of a new feature ...
Cached Medicine News:Health News:PMSI and Ameritox Launch Program to Enhance Quality and Effectiveness of Opioid Therapy 2Health News:PMSI and Ameritox Launch Program to Enhance Quality and Effectiveness of Opioid Therapy 3Health News:Wildlife still exposed to Exxon Valdez oil 20 years after disaster 2Health News:2010 DTC National Advertising Award Winners Honored 2Health News:2010 DTC National Advertising Award Winners Honored 3Health News:Prostate Cancer Patients at Higher Risk of Blood Clots 2Health News:Prostate Cancer Patients at Higher Risk of Blood Clots 3Health News:Worldwide Sales in March Increase Dramatically At Tahitian Noni International 2Health News:GreenEarth Makes Every Day Earth Day with New Online Tools to Live a Greener Life 2Health News:GreenEarth Makes Every Day Earth Day with New Online Tools to Live a Greener Life 3
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Kit for the Preparation of Technetium Tc 99m Sestamibi for injection...
Straight Tip, Measures from 0mm to 20mm in 1mm Increments, Readable on Both Sides, Thumbscrew Lock Holds Desired Setting; in Titanium....
Very fine, blunt tip....
Medicine Products: